^
Association details:
| Biomarker: | Chr del(11q) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + zilovertamab (UC-961) (ROR1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
Published date:
05/28/2021
Excerpt:
...CLL pts in Parts 1 and 2 were high risk as determined by unmutated IGHV, del17p, and/or del11q…. best response of 17 evaluable pts in Parts 1 and 2 included an objective response rate (ORR) of 82%, 41% CR/CMR, 41% PR, 12% SD, and 6% PD. CR/CMR remain durable from 8-28+ mos. Most responses occurred rapidly after ̃3 mos of Cirm/Ibr....Cirm/Ibr is a well-tolerated, active regimen in both MCL and CLL.
DOI:
10.1200/JCO.2021.39.15_suppl.7556
Trial ID:
